by kwal1 | Feb 5, 2016 | News
Montpellier, France, February 5th, 2016. SurgiMab announces the launch of a phase I clinical trial program evaluating the safety and performance of its fluorescent conjugate SGM-101 in patients with pancreatic or rectal cancer. SurgiMab, founded in 2011 in...
by kwal1 | Sep 2, 2015 | News
SurgiMab is happy to be part of the sponsors for the one-day Optical Surgical Navigation Seminar that is organized on september the 2nd during the World Molecular Imaging Congress in Hawaï. SurgiMab will also present its latest results on September 3rd during the WMIC...
by kwal1 | May 15, 2015 | News
SurgiMab, a French company founded in 2011 in Montpellier, is developing antibody-fluorochrome conjugates as in vivo diagnostic agents in oncology. “Today we are pleased to announce that Montpellier Cancer Institute (ICM) has started patient inclusion in a phase I...
by kwal1 | Jul 18, 2014 | News
SurgiMab is happy to announce that it is part of the 15 laureates – selected among 87 young innovative companies – of the NETVA program. NETVA (NEw Technology Venture Accelerator) is a unique program of preparation and exposure to high-tech U.S. markets for...
by kwal1 | May 18, 2014 | News
SurgiMab will attend the 8th “CHIP / HIPEC meeting” that will take place in Montpellier on May 23rd, 2014.